C—Side by side
Compare
Up to four peptides. Opinion rows are labeled. Copy the URL to share.
| Field | BPC-157 | TB-500 |
|---|---|---|
| Type | Research Only | Research Only |
| Regulatory status | Not FDA-approved; no verified marketing authorization | Not FDA-approved; no verified marketing authorization |
| Compounding status | Off Category 2, review pending | Off Category 2, review pending |
| FDA-approved indications | None | None |
| Categories | Healing & repair, GI | Healing & repair |
| Claimed uses |
|
|
| Mechanism | Synthetic pentadecapeptide studied for tissue repair, angiogenesis and nitric-oxide signaling. Proposed mechanisms largely derive from animal and cell experiments. | The LKKTETQ fragment is associated with thymosin beta-4 actin-binding biology. Tissue-repair claims often extrapolate from the full-length protein rather than establish fragment efficacy. |
| Evidence level | Animal studies mostly | Animal studies mostly |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Rising | Watch |
| Routes | Injection, Oral | Injection |
| WADA | Prohibited | Prohibited |
| Where it stands (opinion) | FDA now places BPC-157 in its withdrawn-nomination table, not the active Category 2 table; this is not compounding authorization. WADA 2026 S0 prohibits BPC-157. | FDA lists the fragment among withdrawn nominations. Full-length thymosin beta-4 trials do not validate TB-500; WADA 2026 S2.3 prohibits TB-500. |
| Last reviewed | 2026-10-30 | 2026-10-30 |
| News (30d) | 3 | 1 |